ARGS..Phase3 Trial News The average number of antigen-specific memory T-cells after the seventh dose was approximately double the number observed before treatment. This increase was found to be statistically significant http://crweworld.com/article/news-provided-by-globenewswire/175537/argos-therapeutics-provides-update-on-immunology-data-from-the-phase-3-adapt-trial-presented-at-the-sitc-2017-annual-meeting